In a recent work, the analysis of 636 patients from the International Study to Predict Optimized Treatment in Depression (iSPOT-D), treated 8-week with antidepressants escitalopram (SSRI), sertraline (SSRI), or extended-release venlafaxine (SNRI), have showed a pharmacogenetics association with CRHBP variant rs2836514333. Here, CRHBP is linked to depressive symptom measurement.